ArticlePloS one2025
Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cirrhosis can present with complications such as hyperammonemia and inflammation, and the consequent appearance of minimal hepatic encephalopathy (MHE), which has been associated with poorer motor performance. Our aim was to analyze whether motor impairment would predict blood levels of ammonia and inflammatory factors in cirrhotic patients, independently of cognitive impairment. Blood was extracted from 67 cirrhotic patients from two hospitals in Valencia (Spain) (41.79% with MHE, diagnosis by Psychometric Hepatic Encephalopathy Score). Blood ammonia and plasma levels of interleukins (IL-6, IL-13, IL-18, IL-21, IL-22, IL-23, TNF-α, TGF-β) and chemokines (CCL20, CX3CL1, CXCL13, CCL2) were measured by micro-diffusion and ELISA, respectively. Gait, balance, hand strength, and manual motor speed were evaluated with biomechanical tools. All measurements were performed at University of Valencia, Spain. Motor outcomes were used as predictors in multiple linear regression analysis to determine their predictive capacity on blood ammonia and inflammatory factors. We found that levels of blood ammonia and TNF-α were significantly predicted by the set of motor parameters with a coefficient of determination (R2)>0.50, particularly by balance performance through the movement and velocity of Center of Pressure across the balance test. On the other hand, the models for IL-13, IL-21, CX3CL1, IL-6, CCL2, yielded an R2 varying between 0.31-0.39. Lastly, R2 was between 0.29 and 0.16 for the cytokines CXCL13, IL-22, CCL20, IL-18, and TGF-β. Beside balance outcomes, gait speed and swing phase, as well as grip and lateral pinch strength, and hand motor speed, were frequent predictors in the models calculated. In conclusion, motor performance can predict blood levels of ammonia and cytokines in patients with liver cirrhosis, independently of the cognitive impairment present. Motor impairment could serve as an early, non-invasive indicator of disease severity, indicating the utility of conducting these tests in daily clinical practice and in follow-up studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.